Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Edgewise Therapeutics sells sevasemten to Servier for up to $2.65 billion
June 1, 2026 8:31 AM EDTEdgewise Therapeutics Inc. (NASDAQ: EWTX) announced it entered into a definitive agreement to sell sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments.
Under the agreement, Servier will acquire all rights to sevasemten, including intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting... More
Servier to acquire Edgewise muscular dystrophy business for $2.65 billion
June 1, 2026 8:30 AM EDTServier announced an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ: EWTX) for up to $2.65 billion. The transaction includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments.
The acquisition includes sevasemten, an investigational oral treatment for Becker and... More
